Manufacturer with High Purity and Stable Quality
Chemical Name: Fingolimod Hydrochloride
Synonyms: Fingolimod HCl; FTY 720
CAS: 162359-56-0
Appearance: White to Off-White Powder Purity: ≥99.0% (HPLC)
Fingolimod Hydrochloride is a FDA approved drug for Multiple Sclerosis treatment.
API High Quality, Commercial Production
| Chemical Name |
Fingolimod Hydrochloride |
| Synonyms |
Fingolimod HCl; FTY 720 |
| CAS Number |
162359-56-0 |
| CAT Number |
RF-API39 |
| Stock Status |
In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula |
C19H34ClNO2 |
| Molecular Weight |
343.93 |
| Melting Point |
102.0~107.0°C |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Off-White Powder |
| Solubility |
Completely Soluble in Water |
| Purity / Analysis Method |
≥99.0% (HPLC) |
| Moisture (K.F) |
≤0.50% |
| Residue on Ignition |
≤0.50% |
| Test Standard |
Enterprise Standard |
| Usage |
Active Pharmaceutical Ingredient (API) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Fingolimod Hydrochloride (CAS: 162359-56-0) with high quality.
Fingolimod Hydrochloride is the first oral drug for the treatment of multiple sclerosis. It is successfully developed by the pharmaceutical company Novartis, and it has been approved for marketing by the US Food and Drug Administration (FDA). The recommended dose is 0.5mg once a day for oral administration. Multiple sclerosis is a debilitating neurological disease that can cause the patient to lose a sense of balance, appear muscle spasms and other movement disorders. The disease has been treated with injectable drugs. This kind of medication brought great inconvenience to patients. Fingolimod Hydrochloride is a sphingosine-l-phosphate (S1PR) receptor modulator. After phosphorylation, It is bound to s1P receptor that is on the surface of lymphocyte, which will change lymphocyte migration, and promote cells into the lymphatic tissue, and prevent lymphocytes from leaving the lymphoid tissue and get into the graft. Thereby, it will prevent these cells from infiltrating the central nervous system (CNS), which achieves the effect of immunosuppression. According to the drug's introduction, drugmaker Novartis said that this process of pharmacological effects is reversible. If medication is stopped, the level of lymphocytes in circulating system will return to normal.